BRAF and colorectal carcinoma: The dual inhibition of HER2 (lapatinib and trastuzumab or pertuzumab), but not the simple block, is capable of inducing durable responses in patient-derived xenograft (PDX) models of native RAS/BRAF/PI3K cetuximab-resistant CRC [33].